<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1470-7330-14-S1-O22</article-id><article-id pub-id-type="doi">10.1186/1470-7330-14-S1-O22</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>Whole-body DWI in patients with lymphoma: imaging findings, pitfalls, and limitations</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Rahmouni</surname><given-names>Alain</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>alain.rahmouni@hmn.aphp.fr</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Toledano</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Lin</surname><given-names>Chieh</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Itti</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Haioun</surname><given-names>Corinne</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Luciani</surname><given-names>Alain</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib></contrib-group><aff id="I1"><label>1</label>Departement d&#x02019;Imagerie M&#x000e9;dicale, AP-HP, CHU Henri Mondor, Faculte de Medecine, Universite Paris-Est Creteil, France</aff><aff id="I2"><label>2</label>Department of Nuclear Medicine and Molecular Imaging Center, Chan Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan</aff><aff id="I3"><label>3</label>Departement de Medecine Nucleaire, AP-HP, CHU Henri Mondor, Faculte de Medecine, Universite Paris-Est Creteil, France</aff><aff id="I4"><label>4</label>Departement d&#x02019;Hematologie Clinique, AP-HP, CHU Henri Mondor, Faculte de Medecine, Universite Paris-Est Creteil, France</aff><aff id="I5"><label>5</label>TBC</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2014</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens AG, Healthcare Sector, Imaging and Therapy Division.</named-content></supplement><fpage>O22</fpage><lpage>O22</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Rahmouni et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Rahmouni et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/14/S1/O22"/><conference><conf-date>9-11 October 2014</conf-date><conf-name>International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</conf-name><conf-loc>Heidelberg, Germany</conf-loc></conference></article-meta></front><body><sec><title/><p>Whole body (WB) imaging plays an essential role in the management of lymphoma patients, including defining the full extent of the disease at baseline, allowing for an accurate staging and therefore an adapted treatment strategy, assessing treatment response and detecting relapse. Contrast-enhanced computed tomography (CT) has long been the imaging technique most commonly used for staging and follow up of malignant lymphoma, using International Working Group (IWG) criteria [<xref ref-type="bibr" rid="B1">1</xref>]. However, CT lacks functional and metabolic information, compromising identification of disease in non-enlarged lymph nodes or other organs, as well as sufficient contrast in certain organs as for example the spleen or bone marrow. In 2007, IWG response criteria were revised, incorporating Positron Emission Tomography (PET) with 18-fluorodeoxyglucose (FDG) information [<xref ref-type="bibr" rid="B2">2</xref>], thus combining metabolic information and anatomical data of the CT resulting in a higher accuracy than the both imaging modalities taken separately [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) probes noninvasively the random microscopic motion of water molecules in the body, reflecting cellularity and cell membrane integrity. Because of their high cellularity and high nuclear-to-cytoplasm ratio, lymphomas have a lower apparent diffusion coefficient (ADC) than other tumors [<xref ref-type="bibr" rid="B4">4</xref>]. WB-DW-MRI allows both anatomical information, as well as functional and quantitative evaluation of tumor sites, thanks to the extraction of the apparent diffusion coefficient (ADC). At staging, lymphoma lesions have low ADC value except necrotic areas.</p><p>Recent studies comparing whole-body DWI to PET-CT have demonstrated the potential role of whole-body DWI in routine lymphoma patient care but included only a small number of patients. Using the DWIBS technique (diffusion weighted imaging with background body signal suppression), Abdulqadhr et al. compared whole-body DWI and PET/CT at staging with an agreement in the Ann Arbor stage for 90.3% of patients [<xref ref-type="bibr" rid="B5">5</xref>]. Based on ADC analysis, Lin et al showed an agreement at baseline in 93% of patients [<xref ref-type="bibr" rid="B4">4</xref>]. Response assessment is necessary during therapy to readapt treatment strategy if necessary, and to document a complete remission at the end of treatment. After treatment, an increase in ADC value of residual masses has been demonstrated [<xref ref-type="bibr" rid="B6">6</xref>]. Recent technical breakthroughs in MRI technology such as echo-planar imaging (EPI), high gradient amplitudes, combined phased-array surface coils covering the patient, and parallel imaging, have drastically improved patient comfort and acceptance for whole body MRI [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>], making this technique feasible in clinical routine, illustrating the need for radiologists to get familiar with this technique. As a result, WB-DW-MRI with ADC mapping has become a promising tool for lymphoma staging and re-staging, and response assessment.</p><p>Based on our 4-years experience with WB-DW-MRI applied in Hodgkin and diffuse large B-cell lymphoma patients together with 18FDG-PET/CT, our objective is to offer radiologists the information required to optimize acquisition whole body DWI parameters on both 1.5 and 3T MR systems. We will expose the spectrum of imaging findings and discuss the pitfalls, limitations, and potential challenges of WB-DW-MRI in caring for lymphoma patients.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Cheson</surname><given-names>BD</given-names></name><name><surname>Horning</surname><given-names>SJ</given-names></name><name><surname>Coiffier</surname><given-names>B</given-names></name><name><surname>Shipp</surname><given-names>MA</given-names></name><name><surname>Fisher</surname><given-names>RI</given-names></name><name><surname>Connors</surname><given-names>JM</given-names></name><etal/><article-title>Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>1244</fpage><lpage>1253</lpage><?supplied-pmid 10561185?><pub-id pub-id-type="pmid">10561185</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Cheson</surname><given-names>BD</given-names></name><name><surname>Pfistner</surname><given-names>B</given-names></name><name><surname>Juweid</surname><given-names>ME</given-names></name><name><surname>Gascoyne</surname><given-names>RD</given-names></name><name><surname>Specht</surname><given-names>L</given-names></name><name><surname>Horning</surname><given-names>SJ</given-names></name><etal/><article-title>Revised Response Criteria for Malignant Lymphoma</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>579</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.2403</pub-id><?supplied-pmid 17242396?><pub-id pub-id-type="pmid">17242396</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Haioun</surname><given-names>C</given-names></name><name><surname>Itti</surname><given-names>E</given-names></name><name><surname>Rahmouni</surname><given-names>A</given-names></name><name><surname>Brice</surname><given-names>P</given-names></name><name><surname>Rain</surname><given-names>JD</given-names></name><name><surname>Belhadj</surname><given-names>K</given-names></name><name><surname>Gaulard</surname><given-names>P</given-names></name><name><surname>Garderet</surname><given-names>L</given-names></name><name><surname>Lepage</surname><given-names>E</given-names></name><name><surname>Reyes</surname><given-names>F</given-names></name><name><surname>Meignan</surname><given-names>M</given-names></name><article-title>[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>1376</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-01-0272</pub-id><?supplied-pmid 15860666?><pub-id pub-id-type="pmid">15860666</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Luciani</surname><given-names>A</given-names></name><name><surname>Itti</surname><given-names>E</given-names></name><name><surname>El-Gnaoui</surname><given-names>T</given-names></name><name><surname>Vignaud</surname><given-names>A</given-names></name><name><surname>Beaussart</surname><given-names>P</given-names></name><etal/><article-title>Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma</article-title><source>Eur Radiol</source><year>2010</year><volume>20</volume><fpage>2027</fpage><lpage>2038</lpage><pub-id pub-id-type="doi">10.1007/s00330-010-1758-y</pub-id><?supplied-pmid 20309558?><pub-id pub-id-type="pmid">20309558</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Abdulqadhr</surname><given-names>G</given-names></name><name><surname>Molin</surname><given-names>D</given-names></name><name><surname>Astrom</surname><given-names>G</given-names></name><name><surname>Suurkula</surname><given-names>M</given-names></name><name><surname>Johansson</surname><given-names>L</given-names></name><name><surname>Hagberg</surname><given-names>H</given-names></name><etal/><article-title>Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients</article-title><source>Acta Radiol</source><year>2011</year><volume>52</volume><fpage>173</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1258/ar.2010.100246</pub-id><?supplied-pmid 21498346?><pub-id pub-id-type="pmid">21498346</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Itti</surname><given-names>E</given-names></name><name><surname>Luciani</surname><given-names>A</given-names></name><name><surname>Zegai</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>S-J</given-names></name><name><surname>Kuhnowski</surname><given-names>F</given-names></name><name><surname>Rahmouni</surname><given-names>A</given-names></name><article-title>Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study</article-title><source>Invest Radiol</source><year>2011</year><volume>46</volume><fpage>341</fpage><lpage>349</lpage><?supplied-pmid 21263330?><pub-id pub-id-type="pmid">21263330</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Koh</surname><given-names>D-M</given-names></name><name><surname>Collins</surname><given-names>DJ</given-names></name><article-title>Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology</article-title><source>AJR</source><year>2007</year><volume>188</volume><fpage>1622</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.2214/AJR.06.1403</pub-id><?supplied-pmid 17515386?><pub-id pub-id-type="pmid">17515386</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Padhani</surname><given-names>AR</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Koh</surname><given-names>D-M</given-names></name><name><surname>Chenevert</surname><given-names>TL</given-names></name><name><surname>Thoeny</surname><given-names>HC</given-names></name><name><surname>Takahara</surname><given-names>T</given-names></name><etal/><article-title>Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations</article-title><source>Neoplasia</source><year>2009</year><volume>11</volume><fpage>102</fpage><lpage>125</lpage><?supplied-pmid 19186405?><pub-id pub-id-type="pmid">19186405</pub-id></mixed-citation></ref></ref-list></back></article>
